Clinical Trials Browser

Kidney Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Transitional Cell, Neoplasm Metastasis

Prostatic Neoplasms

First-line Non-small-cell Lung Cancer

Castration Resistant Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Prostatic Neoplasms

Insulin Resistance, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

Carcinoma, Transitional Cell

Prostatic Neoplasms

Carcinoma, Renal Cell

Carcinoma, Transitional Cell

Carcinoma, Renal Cell, Kidney Neoplasms

Prostate Adenocarcinoma

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Kidney Neoplasms

Carcinoma, Renal Cell

Prostatic Neoplasms

Prostatic Neoplasms

Kidney Neoplasms, Melanoma

Prostatic Neoplasms

Metastatic Bladder Urothelial Carcinoma

Urinary Bladder Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Adenoviridae Infections, Urinary Bladder Neoplasms

Clinical Trials

Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

HARMONY

Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology

REPRESENTATION

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

TALON

AVENTURINE

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer

MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

CANUCK-01

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

CARMA

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Insulin Resistance and Androgen Deprivation Therapy

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

AVENU

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

AtezoVax

Focal Therapy for Prostate Cancer

LIGAND

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

AERA

DOMINATION

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

PIVOT-RCC

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

exBOND